Phase 2 N=6 DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
Breast Cancer
Primary: Change in HIF-1α Protein Expression
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Peripheral Artery Disease (PAD); Intermittent Claudication
Primary: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths — 18; 17; 4; 4 Participants
Phase 2 N=198 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Sickle Cell Disease
Primary: Annual Rate of Sickle Cell-related Pain Crises (SCPC) Per Hodges-Lehmann Median — 1.63; 2.01; 2.98 SCPC per year — p== 0.010
Phase 2 N=22 A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions — 622.8; 867 ug/ml
Phase 2 N=55 Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Leukemia · Lymphoma
Primary: Number of Participants (Incidence) of LTLS (Laboratory Tumor Lysis Syndrome) — 1; 1 Participants
Phase 2 N=318 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Response Rate — 89 percentage of patients
Phase 2 N=81 Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Primary: Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time — 239; 179; 208; 222 ng/mL
Phase 2 N=48 A Phase II Study of Neoadjuvant FOLFIRINOX
Resectable Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants
Phase 2 N=291 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
Chronic Insomnia · Adults · Elderly
Primary: Probability of Having Utility Function Greater Than (>) 1 Based on Bayesian Analysis — 0.8789; 0.8920; 0.9032; 0.9406 probability
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=24 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
Leukemia, Lymphocytic, Chronic, B-Cell · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Incidence and Severity of Adverse Events (AEs) — 11; 13 Participants
Phase 2 N=243 Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (mL) at Week 48 Using the Missing, Switch, Discontinuation Equals Failure (MSDF)…
Phase 2 N=32 Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1 (PH1)
Primary: Number of Participants With Adverse Events (AEs) — 5; 6; 2; 6 Participants
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Phase 2 N=233 A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Lung Cancer
Primary: Objective Response Rate (ORR) of Pembrolizumab + Chemotherapy + Epacadostat Versus Pembrolizumab + Chemotherapy + Placebo — 26.4; 44.8 percentage of participants…